척수성 근위축증 치료 시장 규모, 점유율, 성장 및 세계 업계 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of spinal muscular atrophy treatment Market

The global spinal muscular atrophy treatment market size was valued at USD 5.25 billion in 2025 and is projected to reach USD 6.26 billion in 2026, expanding to USD 25.72 billion by 2034. The market is expected to register a CAGR of 19.31% during 2026-2034. North America dominated the global market with a 49.65% market share in 2025, supported by early approvals of advanced therapies, favorable reimbursement policies, and increasing patient treatment rates.

Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disorder that can cause progressive muscle weakness and severe disability, particularly in infants with Type 1 SMA. The increasing incidence of SMA, growing awareness, improved diagnosis, and the availability of disease-modifying therapies are strengthening market growth. High-value treatments such as Spinraza and Zolgensma have significantly transformed the treatment landscape and increased the value of the global SMA treatment market.

Market Trends

A major spinal muscular atrophy treatment market trend is the increasing investment in research and development for innovative therapies. Pharmaceutical companies are developing pipeline candidates designed to improve treatment efficacy, accessibility, and patient outcomes. The emergence of gene therapy and other advanced therapeutic approaches is creating new opportunities across the SMA treatment industry.

Another important trend is the expansion of reimbursement access. Several countries have introduced reimbursement programs for expensive SMA therapies, improving patient access to advanced treatments. Greater reimbursement coverage is expected to support treatment adoption, particularly in developed healthcare markets.

Market Drivers

Growing Incidence and Awareness of SMA:

The increasing diagnosis of spinal muscular atrophy is supporting demand for effective therapies. Rising awareness among healthcare professionals and families regarding the severity of SMA is encouraging earlier diagnosis and treatment.

Launch of Advanced and Highly Effective Therapies:

The introduction of Spinraza (Nusinersen) and Zolgensma (Onasemnogene abeparvovec) has substantially changed the SMA treatment landscape. Their ability to address the underlying disease mechanism and improve patient outcomes is supporting market growth.

Market Restraints and Challenges

High Treatment Costs:

The extremely high cost of approved SMA therapies remains a significant restraint. Spinraza can involve substantial recurring treatment costs, while Zolgensma has historically carried a one-time treatment price of approximately USD 2.1 million. These costs can limit accessibility in countries with restricted healthcare budgets or inadequate reimbursement coverage.

Other challenges include regulatory complexity, limited awareness in developing regions, delayed diagnosis, and the need for specialized treatment infrastructure.

Segmentation Analysis

By Product:

The market is segmented into Nusinersen and Onasemnogene Abeparvovec. Nusinersen held the largest historical share due to its earlier market approval and widespread adoption. Onasemnogene Abeparvovec is expected to gain momentum as gene therapy adoption expands across additional markets.

By Disease Type:

The market includes Type 1 SMA, Type 2 SMA, and Others. Type 1 SMA held the dominant position because of the severity and high treatment requirements associated with this form of the disease.

By Distribution Channel:

Distribution channels include hospital pharmacies, retail pharmacies, and others. Hospital pharmacies have historically maintained the leading position because SMA therapies require administration and monitoring by trained healthcare professionals.

Regional Analysis

North America represented the leading regional market, accounting for 49.65% of the global market in 2025. The region benefits from early regulatory approvals, advanced healthcare infrastructure, favorable reimbursement policies, and increasing treatment rates.

Europe is expected to remain the second-largest regional market, supported by increasing reimbursement access and strong healthcare systems.

Asia Pacific is projected to experience significant growth as governments and private organizations increase funding for rare-disease treatments. Japan has supported reimbursed access to SMA therapies, while improving treatment accessibility in other Asian markets is expected to create further opportunities.

Latin America is benefiting from increasing disease awareness, while the Middle East & Africa market is expected to experience slower-to-moderate growth because of delayed diagnosis and limited healthcare infrastructure in several countries.

Key Industry Players

Major companies operating in the SMA treatment market include Biogen, Novartis AG, Genentech/F. Hoffmann-La Roche Ltd, Astellas Pharma Inc., and Genzyme Corporation. Biogen and Novartis have maintained strong competitive positions through Spinraza and Zolgensma, while other pharmaceutical companies continue developing pipeline therapies.

Recent Industry Developments

In May 2019, Novartis' Zolgensma received U.S. FDA approval as a gene therapy for pediatric patients with SMA. In December 2016, the U.S. FDA approved Biogen's Spinraza as the first drug specifically approved for the treatment of spinal muscular atrophy.

Future Outlook

The spinal muscular atrophy treatment market outlook remains strong due to increasing diagnosis, continued clinical research, product launches, expanding reimbursement programs, and growing adoption of gene therapies. The market is expected to expand from USD 5.25 billion in 2025 to USD 6.26 billion in 2026 and USD 25.72 billion by 2034. Increasing investment in rare-disease research and the development of more accessible treatment options will remain important factors shaping the market.

Conclusion

The global spinal muscular atrophy treatment market is entering a strong growth phase, supported by advanced therapies, increasing disease awareness, improved diagnosis, and expanding reimbursement coverage. North America currently represents the leading market, while Asia Pacific offers significant future opportunities as treatment accessibility improves. Although high therapy costs remain a major challenge, continued innovation in gene therapy, pipeline development, and supportive healthcare policies are expected to drive substantial market expansion through 2034.

Unit Value (USD million)

Segmentation By Product

• Nusinersen
• Onasemnogen Abeparvovec

By Disease Type

• Type 1 SMA
• Type 2 SMA
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, and Rest of Asia Pacific)
• Rest of the World

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Spinal Muscular Atrophy for Key Countries
• 4.2. Key Industry Developments
• 4.3. Pipeline Analysis
• 4.4. New Product Launches
• 4.5. Reimbursement Scenario by Key Countries
• 4.6. Regulatory Scenario
• 4.7. Key Industry Trends

5. Global Spinal Muscular Atrophy (SMA) Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Product Type
  • 5.2.1. Nusinersen
  • 5.2.2. Onasemnogen Abeparvovec
• 5.3. Market Analysis, Insights and Forecast - By Disease Type
  • 5.3.1. Type 1 SMA
  • 5.3.2. Type 2 SMA
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Rest of the World

6. North America Spinal Muscular Atrophy (SMA) Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Product Type
  • 6.2.1. Nusinersen
  • 6.2.2. Onasemnogen Abeparvovec
• 6.3. Market Analysis - By Disease Type
  • 6.3.1. Type 1 SMA
  • 6.3.2. Type 2 SMA
  • 6.3.3. Others
• 6.4. Market Analysis - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail Pharmacies
  • 6.4.3. Others
• 6.5. Market Analysis - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Spinal Muscular Atrophy (SMA) Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Product Type
  • 7.2.1. Nusinersen
  • 7.2.2. Onasemnogen Abeparvovec
• 7.3. Market Analysis - By Disease Type
  • 7.3.1. Type 1 SMA
  • 7.3.2. Type 2 SMA
  • 7.3.3. Others
• 7.4. Market Analysis - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies
  • 7.4.3. Others
• 7.5. Market Analysis - By Country/ sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Rest of Europe

8. Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Product Type
  • 8.2.1. Nusinersen
  • 8.2.2. Onasemnogen Abeparvovec
• 8.3. Market Analysis - By Disease Type
  • 8.3.1. Type 1 SMA
  • 8.3.2. Type 2 SMA
  • 8.3.3. Others
• 8.4. Market Analysis - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies
  • 8.4.3. Others
• 8.5. Market Analysis - By Country/ sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Rest of Asia Pacific

9. Rest of the World Spinal Muscular Atrophy (SMA) Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Product Type
  • 9.2.1. Nusinersen
  • 9.2.2. Onasemnogen Abeparvovec
• 9.3. Market Analysis - By Disease Type
  • 9.3.1. Type 1 SMA
  • 9.3.2. Type 2 SMA
  • 9.3.3. Others
• 9.4. Market Analysis - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies
  • 9.4.3. Others

10. Competitive Analysis

• 10.1. Key Industry Developments
• 10.2. Global Market Share Analysis (2025)
• 10.3. Competition Dashboard
• 10.4. Comparative Analysis - Major Players
• 10.5. Company Profiles
  • 10.5.1. Biogen
    • 10.5.1.1. Overview,
    • 10.5.1.2. Products & services,
    • 10.5.1.3. SWOT analysis,
    • 10.5.1.4. Recent developments,
    • 10.5.1.5. strategies,
    • 10.5.1.6. financials (based on availability)
  • 10.5.2. Novartis AG
    • 10.5.2.1. Overview,
    • 10.5.2.2. Products & services,
    • 10.5.2.3. SWOT analysis,
    • 10.5.2.4. Recent developments,
    • 10.5.2.5. strategies,
    • 10.5.2.6. financials (based on availability)
  • 10.5.3. Genentech, Inc./ F. Hoffmann-La Roche Ltd
    • 10.5.3.1. Overview,
    • 10.5.3.2. Products & services,
    • 10.5.3.3. SWOT analysis,
    • 10.5.3.4. Recent developments,
    • 10.5.3.5. strategies,
    • 10.5.3.6. financials (based on availability)
  • 10.5.4. Astellas Pharma Inc.
    • 10.5.4.1. Overview,
    • 10.5.4.2. Products & services,
    • 10.5.4.3. SWOT analysis,
    • 10.5.4.4. Recent developments,
    • 10.5.4.5. strategies,
    • 10.5.4.6. financials (based on availability)
  • 10.5.5. Genzyme Corporation
    • 10.5.5.1. Overview,
    • 10.5.5.2. Products & services,
    • 10.5.5.3. SWOT analysis,
    • 10.5.5.4. Recent developments,
    • 10.5.5.5. strategies,
    • 10.5.5.6. financials (based on availability)
  • 10.5.6. Other Prominent Players
    • 10.5.6.1. Overview,
    • 10.5.6.2. Products & services,
    • 10.5.6.3. SWOT analysis,
    • 10.5.6.4. Recent developments,
    • 10.5.6.5. strategies,
    • 10.5.6.6. financials (based on availability)